Keyword: Axovant Sciences
The deal accelerates Axovant’s evolution into a gene therapy specialist by giving it control of two assets that are in or near the clinic.
Axovant has halted development of nelotanserin after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia.
Abeona fires CEO Carsten Thiel; MHRA CEO to leave in wake of Brexit; Lilly CMO to lead Brickell Bio; and Janssen's discovery head joins Incyte.
After refocusing on gene therapy, Axovant is appointing five new executives to posts ranging from clinical development to commercial operations.
The gene therapy suppresses expression of a mutated protein and encourages production of a functional version, thereby lessening muscular problems.
Roivant will shed around 10% of its staff and cede responsibility for others to the heads of its portfolio of startups.
Celgene's shake-ups continue with new CFO, Zai Lab grabs top AZ exec, Axovant brings on Spark co-founder as CTO, and Gilead promotes its top dealmaker.
Axovant is continuing its change-up with a new focus and a new exec.
Novartis' ex-oncology head jumps to startup; Axovant poaches Allergan's CMO; and Biogen brings on Pfizer dealmaker.
Alzheimer’s startup Cortexyme rounded up $76 million for a potentially first-in-class antibiotic treatment, while others struggle in the field.